Cargando…

Triple-Negative Breast Cancer: Assessing the Role of Immunohistochemical Biomarkers on Neoadjuvant Treatment

OBJECTIVE: This study aimed to investigate the influence of immunohistochemical (IHC) biomarkers in the response to neoadjuvant chemotherapy (NACT) and survival outcomes in the subset of locally advanced triple-negative breast cancer (TNBC). MATERIALS AND METHODS: The epidermal growth factor recepto...

Descripción completa

Detalles Bibliográficos
Autores principales:	da Silva, Jesse Lopes, Rodrigues, Fabiana Resende, de Mesquita, Guilherme Gomes, Fernandes, Priscila Valverde, Thuler, Luiz Claudio Santos, de Melo, Andreia Cristina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810824/ https://www.ncbi.nlm.nih.gov/pubmed/33469357 http://dx.doi.org/10.2147/BCTT.S287320

Ejemplares similares

Prognostic Influence of Residual Tumor-Infiltrating Lymphocyte Subtype After Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications
por: da Silva, Jesse Lopes, et al.
Publicado: (2023)

Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort
por: da Silva, Jesse Lopes, et al.
Publicado: (2020)

The prevalence and prognostic impact of tumor-infiltrating lymphocytes in uterine carcinosarcoma
por: da Silva, Jesse Lopes, et al.
Publicado: (2021)

Evolving Evidence for the Optimization of Neoadjuvant Therapy in Triple-Negative Breast Cancer
por: Silva, Diogo, et al.
Publicado: (2022)

Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors
por: Brandi, Andressa, et al.
Publicado: (2022)

Gynecologic cancer in Brazil and the law of sixty days
por: Paulino, Eduardo, et al.
Publicado: (2018)

Neoadjuvant immunotherapy in early-stage triple negative breast cancer
por: Laouris, Panayiotis, et al.
Publicado: (2023)

Overview of Adult Sarcoma Burden and Clinical Pathways in Brazil
por: David, Bruna Bianca Lopes, et al.
Publicado: (2022)

Epidemiology of uveal melanoma in Brazil
por: Lucena, Evandro, et al.
Publicado: (2020)

Epidemiological profile of mucosal melanoma in Brazil
por: Cohen Goldemberg, Daniel, et al.
Publicado: (2020)

Panorama of Gynecologic Cancer in Brazil
por: Paulino, Eduardo, et al.
Publicado: (2020)

Clinicopathlogic and Immunohistochemical Characteristics of Triple Negative Invasive Lobular Carcinoma
por: Koo, Ja Seung, et al.
Publicado: (2011)

Triple-Negative Breast Cancer: An Update on Neoadjuvant Clinical Trials
por: Amos, Keith D., et al.
Publicado: (2012)

Controversial issues in the neoadjuvant treatment of triple-negative breast cancer
por: Fitzpatrick, Amanda, et al.
Publicado: (2019)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
por: Tischkowitz, Marc, et al.
Publicado: (2007)

Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer
por: Sjekloča, Nikoleta, et al.
Publicado: (2020)

Immunohistochemical analysis of CD155 expression in triple-negative breast cancer patients
por: Yoshikawa, Katsuhiro, et al.
Publicado: (2021)

Programmed cell death protein 1 is a marker for neoadjuvant chemotherapy response in triple-negative breast cancer
por: Gaui, Maria de Fátima Dias, et al.
Publicado: (2023)

Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Vernaci, Grazia, et al.
Publicado: (2023)

Prognostic factors associated with overall survival in patients with oral cavity squamous cell carcinoma
por: Oliveira, Letícia L., et al.
Publicado: (2020)

Exploring biomarkers and prognostic factors in uterine carcinosarcoma: An insight into L1CAM, CDX2, p53, and MSI status
por: da Silva, Jesse Lopes, et al.
Publicado: (2023)

Tumor infiltrating lymphocytes in triple negative breast cancer receiving neoadjuvant chemotherapy
por: Castaneda, Carlos A, et al.
Publicado: (2016)

Triple negative breast cancer subtypes and pathologic complete response rate to neoadjuvant chemotherapy
por: Santonja, Angela, et al.
Publicado: (2018)

The Role of Carboplatin in the Neoadjuvant Chemotherapy Treatment of Triple Negative Breast Cancer
por: Castrellon, Aurelio Bartolome, et al.
Publicado: (2017)

Neoadjuvant Treatment for Triple Negative Breast Cancer: Recent Progresses and Challenges
por: Lee, Jin Sun, et al.
Publicado: (2020)

Immune responses during neoadjuvant chemotherapy in triple negative breast cancer
por: Ghallab, Ahmed
Publicado: (2020)

Therapeutic pattern and progress of neoadjuvant treatment for triple-negative breast cancer
por: Xiao, Yan, et al.
Publicado: (2022)

Efficacy and prognostic factors of neoadjuvant chemotherapy for triple-negative breast cancer
por: Ding, Feng, et al.
Publicado: (2022)

The Immunomodulatory Effects of Dexamethasone on Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer
por: Johnson, Kai Conrad Cecil, et al.
Publicado: (2023)

Notch-based gene signature for predicting the response to neoadjuvant chemotherapy in triple-negative breast cancer
por: Omar, Mohamed, et al.
Publicado: (2023)

Topographic expression of the Hippo transducers TAZ and YAP in triple-negative breast cancer treated with neoadjuvant chemotherapy
por: Vici, Patrizia, et al.
Publicado: (2016)

Lack of prognostic significance of adiponectin immunohistochemical expression in patients with triple-negative breast cancer
por: Cubukcu, Erdem, et al.
Publicado: (2014)

A Novel Subset of Triple-Negative Breast Cancers with Unique Histology and Immunohistochemical Expression
por: Kalyanasundaram, Swaminathan, et al.
Publicado: (2022)

Blood-based genomics of triple-negative breast cancer progression in patients treated with neoadjuvant chemotherapy
por: Ortolan, E., et al.
Publicado: (2021)

Neoadjuvant eribulin mesylate following anthracycline and taxane in triple negative breast cancer: Results from the HOPE study
por: Di Cosimo, Serena, et al.
Publicado: (2019)

Cisplatin as neoadjuvant chemotherapy in triple negative breast cancer: Exciting early results
por: Goel, Arun Kumar, et al.
Publicado: (2010)

Neoadjuvant Therapy in Operable Breast Cancer: Application to Triple Negative Breast Cancer
por: Ademuyiwa, Foluso O., et al.
Publicado: (2013)

BRCAness and Prognosis in Triple-Negative Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Tanino, Hirokazu, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_cq6da7sce60k578ajp6rsqjjl2